M Bohn, KT Kraemer… - US Patent App. 13/018,417, 2011 - Google Patents US 20110112153A1 (i9) United States (12) Patent Application Publication oo) Pub. No.: US 2011/0112153 Al Bohn et al. (43) Pub. Date: May 12,2011 (54) USE OF l-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS (76) Inventors: Manfred Bohn, ... All 2 versions
EE Brodell, E Smith… - Archives of dermatology, 2011 - Am Med Assoc Fluorouracil effectively destroys clinical and subclinical actinic keratoses (AKs) by targeting rapidly proliferating cells while sparing normal skin. This effect was initially reported in patients treated with systemic fluorouracil for solid internal malignant neoplasms. 1 Subsequently, topical ... Related articles - All 3 versions
MA Ionescu, A Baroni, L Brambilla… - Giornale italiano di …, 2011 - ncbi.nlm.nih.gov AIM: Seborrheic dermatitis is a chronic inflammatory disease aggravated by Malassezia species. Toll-like receptors (TLR) are part of innate immune system that can be activated by yeasts. Previous studies showed that an association of Ombelliferae extract with a lipid ( ...
BE Elewski… - Journal of drugs in dermatology: JDD, 2011 - ncbi.nlm.nih.gov Objectives: To demonstrate the efficacy and evaluate the safety of sertaconazole nitrate cream 2% in the treatment of seborrheic dermatitis (SD). Design: Single-center, open-label study. Setting: One academic medical center. Participants: Twenty adult male and female ...
JT Huang, A Rademaker… - Archives of dermatology, 2011 - Am Med Assoc ... Comment. The epidermis in both AKs and areas of ac- tive seborrheicdermatitis proliferates rapidly. ... At a minimum, patients can be warned to expect inflammation to occur in areas of seborrheicdermatitis as well as in clinical and subclinical AKs. ... All 4 versions